| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 31/01/2025 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | NASDAQ:SCLX | Scilex Holding Company |
| 22/01/2025 | 14:00 | GlobeNewswire Inc. | Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication | NASDAQ:SCLX | Scilex Holding Company |
| 21/01/2025 | 17:49 | GlobeNewswire Inc. | Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) | NASDAQ:SCLX | Scilex Holding Company |
| 21/01/2025 | 15:46 | GlobeNewswire Inc. | Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 | NASDAQ:SCLX | Scilex Holding Company |
| 21/01/2025 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC | NASDAQ:SCLX | Scilex Holding Company |
| 21/01/2025 | 13:00 | GlobeNewswire Inc. | Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication | NASDAQ:SCLX | Scilex Holding Company |
| 21/01/2025 | 12:00 | GlobeNewswire Inc. | Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 | NASDAQ:SCLX | Scilex Holding Company |
| 16/01/2025 | 21:38 | GlobeNewswire Inc. | Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults | NASDAQ:SCLX | Scilex Holding Company |
| 13/01/2025 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch | NASDAQ:SCLX | Scilex Holding Company |
| 08/01/2025 | 22:00 | GlobeNewswire Inc. | Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination | NASDAQ:SCLX | Scilex Holding Company |
| 30/12/2024 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 t | NASDAQ:SCLX | Scilex Holding Company |
| 16/12/2024 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation | NASDAQ:SCLX | Scilex Holding Company |
| 13/12/2024 | 18:23 | GlobeNewswire Inc. | Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering | NASDAQ:SCLX | Scilex Holding Company |
| 12/12/2024 | 14:21 | GlobeNewswire Inc. | Scilex Holding Company Announces $17 Million Registered Direct Offering | NASDAQ:SCLX | Scilex Holding Company |
| 11/12/2024 | 18:49 | GlobeNewswire Inc. | Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 | NASDAQ:SCLX | Scilex Holding Company |
| 11/12/2024 | 13:30 | GlobeNewswire Inc. | Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trial | NASDAQ:SCLX | Scilex Holding Company |
| 10/12/2024 | 13:00 | GlobeNewswire Inc. | Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neuro | NASDAQ:SCLX | Scilex Holding Company |
| 22/11/2024 | 12:00 | GlobeNewswire Inc. | Scilex Holding Company Announces Receipt of Notice from Nasdaq | NASDAQ:SCLX | Scilex Holding Company |
| 15/11/2024 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024 | NASDAQ:SCLX | Scilex Holding Company |
| 06/11/2024 | 18:24 | GlobeNewswire Inc. | Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously | NASDAQ:SCLX | Scilex Holding Company |
| 30/10/2024 | 11:00 | GlobeNewswire Inc. | Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (L | NASDAQ:SCLX | Scilex Holding Company |
| 29/10/2024 | 11:00 | GlobeNewswire Inc. | Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock | NASDAQ:SCLX | Scilex Holding Company |
| 28/10/2024 | 11:00 | GlobeNewswire Inc. | Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary | NASDAQ:SCLX | Scilex Holding Company |
| 16/10/2024 | 19:40 | AllPennyStocks.com | Holding Company Shares Rally Following Board Of Directors Commentary | NASDAQ:SCLX | Scilex Holding Company |
| 16/10/2024 | 13:00 | GlobeNewswire Inc. | Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securiti | NASDAQ:SCLX | Scilex Holding Company |
| 16/10/2024 | 10:00 | GlobeNewswire Inc. | Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur a | NASDAQ:SCLX | Scilex Holding Company |
| 08/10/2024 | 19:58 | GlobeNewswire Inc. | Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 | NASDAQ:SCLX | Scilex Holding Company |
| 08/10/2024 | 17:50 | GlobeNewswire Inc. | Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing | NASDAQ:SCLX | Scilex Holding Company |
| 07/10/2024 | 15:52 | GlobeNewswire Inc. | Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile | NASDAQ:SCLX | Scilex Holding Company |
| 26/09/2024 | 15:00 | GlobeNewswire Inc. | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 | NASDAQ:SCLX | Scilex Holding Company |
